Marketing – Page 2 – News & Updates

Pfizer’s XELJANZ® (Tofacitinib) Receives Marketing Authorization in the European Union for the Treatment of Active Ankylosing Spondylitis

adminNovember 22, 202101.3k views

Abstract: The European Commission has approved Pfizer`s first-of-its-kind oral Janus kinase (JAK) inhibitor XELJANZ® (Tofacitinib) 5 mg twice daily for the treatment…

The European Commission Grants Marketing Authorization for VUMERITY® (Diroximel Fumarate) as Oral Treatment for Relapsing-Remitting Multiple Sclerosis.

adminNovember 19, 202101.2k views

SYNOPSIS: VUMERITY is a next-generation oral fumarate treatment for people with relapsing-remitting MS with established efficacy and well-characterized safety, building on Biogen’s…

European Commission approves AbbVie’s Skyrizi (Risankizumab) to Treat Adults with Active Psoriatic Arthritis.

adminNovember 18, 202102.2k views

KEYPOINTS: AbbVie announces that the European Commission (EC) has approved SKYRIZI (Risankizumab, 150 mg, subcutaneous injection at week 0, week 4, and…